Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

Plans to build a long-promised biological manufacturing facility in Manhattan have fizzled, though company leaders prefer not ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. resulting from allegations that ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...